Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase Ib study of intravenous copanlisib in Japanese patients with relapsed/refractory indolent B-cell non-Hodgkin lymphomas
jRCT2080222749Phase 2Completed
- Sponsor
- Bayer
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of copanlisib in mature B-cell lymphoma, follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 2 more, sponsored by Bayer. Primary endpoints: Recommended dose determination and Objective response rate (ORR). Started Feb 2015; status: completed.
02
Drugs
copanlisib
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)Waldenström macroglobulinemia (WM)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on jRCT2080222749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222749.